Vinay Chitkara, MD
Cardiology · London, OHNPI 1659336337
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Penumbra, Inc. at 49.4% of the total.
Across 121 payments — averaging $68.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$4K
- Abbott$2K
- Cardiovascular Systems Inc.$750
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$379
- Boston Scientific$297
- Novartis$209
- plus $674 from 10 others
What the payments were for
- Travel & lodging$4,82758%
- Food & beverage$3,48342%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 12 | $4,114 |
| Abbott | 29 | $1,901 |
| Cardiovascular Systems Inc. | 10 | $750 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $379 |
| Boston Scientific | 2 | $297 |
| Novartis | 13 | $209 |
| Inari Medical, Inc. | 1 | $144 |
| Pfizer | 5 | $90 |
| Abiomed | 3 | $79 |
| Amgen | 4 | $74 |
| Veryan Medical Incorporated | 1 | $67 |
| E.r. Squibb & Sons, L.L.C. | 2 | $59 |
| AstraZeneca | 3 | $56 |
| Merck | 2 | $42 |
| Vital Connect, Inc | 1 | $32 |
| Johnson & Johnson | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,325 in reported general payments places this provider in the 85th percentile of 30 cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 816 | $712,201 |
| XareltoRivaroxaban | 58 | $63,919 |
| Repatha SureclickEvolocumab | 35 | $31,808 |
| EntrestoSacubitril/Valsartan | 16 | $13,088 |
| BrilintaTicagrelor | 19 | $7,988 |
| Metoprolol Succinate | 622 | $7,443 |
| Clonidine | 21 | $4,866 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 128 | $3,421 |
| Amiodarone Hcl | 58 | $3,074 |
| SotalolSotalol Hcl | 172 | $2,915 |
| Atorvastatin Calcium | 261 | $2,655 |
| Potassium Chloride | 153 | $2,626 |
| ClopidogrelClopidogrel Bisulfate | 252 | $2,488 |
| Amlodipine Besylate | 269 | $2,347 |
| Losartan Potassium | 189 | $1,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $90 | $712,201816 claims |
| Johnson & JohnsonXarelto | $30 | $63,91958 claims |
| NovartisEntresto | $209 | $13,08816 claims |
| AstraZenecaBrilinta | $56 | $7,98819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 cardiology providers in Ohio.
Other cardiology in London
- Luis Augusto Palma DallanCleveland$61K
- Rafel El-AtassiElyria$23K
- Haytham MouslyCleveland$17K
- Mazen MahjoubWarren$9K
- Farshad ForouzandehParma$6K
- Vijay RavipatiColumbus$3K
- Basel MoussaFairview Park$2K
- Robert OkyereCleveland$102
- William MarshallColumbus$0
- Scott MaffettColumbus$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.